Works matching IS 01676997 AND DT 2025 AND VI 43 AND IP 1

Results: 19

Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 147, doi. 10.1007/s10637-025-01505-y

By:

Kaneda, Hiroyasu;
Daga, Haruko;
Okada, Asuka;
Nakatani, Yuki;
Tani, Yoko;
Oka, Takako;
Sawa, Kenji;
Sakai, Kazuko;
Nishio, Kazuto;
Kawaguchi, Tomoya

Publication type:

Article

Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 167, doi. 10.1007/s10637-024-01504-5

By:

Tang, Minhong;
Crown, John;
Duffy, Michael J.

Publication type:

Article

Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 118, doi. 10.1007/s10637-024-01503-6

By:

Shimomura, Kazuhiro;
Ogata, Takatsugu;
Maeda, Akimitsu;
Narita, Yukiya;
Taniguchi, Hiroya;
Murotani, Kenta;
Fujiwara, Yutaka;
Tajika, Masahiro;
Hara, Kazuo;
Muro, Kei;
Uchida, Kosaku

Publication type:

Article

Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 93, doi. 10.1007/s10637-024-01502-7

By:

Yu, Zeyu;
Leng, Bin;
You, Ran;
Wang, Chendong;
Diao, Lingfeng;
Xu, Qingyu;
Yin, Guowen

Publication type:

Article

Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 135, doi. 10.1007/s10637-024-01501-8

By:

Banchi, Marta;
Cox, Maria Christina;
Bandini, Arianna;
Orlandi, Paola;
Tacchi, Costanza;
Stefanelli, Fabio;
Chericoni, Silvio;
Bocci, Guido

Publication type:

Article

Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 101, doi. 10.1007/s10637-024-01500-9

By:

Taniguchi, Yoshihiko;
Tamiya, Akihiro;
Osuga, Mitsuo;
Isa, Shun-ichi;
Nakamura, Keiichi;
Mizumori, Yasuyuki;
Shinohara, Tsutomu;
Yanai, Hidetoshi;
Nakatomi, Katsumi;
Oki, Masahide;
Mori, Masahide;
Kuwako, Tomohito;
Yamazaki, Koji;
Shimada, Masahiro;
Ando, Masahiko;
Koh, Yasuhiro

Publication type:

Article

Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 74, doi. 10.1007/s10637-024-01499-z

By:

Wu, Zhaoquan;
Li, Xiting;
Huang, Rui;
He, Binsheng;
Wang, Chunjiang

Publication type:

Article

Immunotherapy in thymic epithelial tumors: an attractive dilemma.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 69, doi. 10.1007/s10637-024-01497-1

By:

Damaj, Nahed;
Nassar, Dany;
Chamaa, Bilal;
Kattan, Joseph

Publication type:

Article

Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 50, doi. 10.1007/s10637-024-01496-2

By:

Sun, Yue;
Wei, Liangliang;
Liu, Hao;
Zong, Gaoyang;
Xia, Zhihao;
Li, Xiangyang;
Yin, Zhanhai;
Huang, Dageng;
Zhang, Yan

Publication type:

Article

Clinical features, treatment, and outcomes of nivolumab induced psoriasis.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 42, doi. 10.1007/s10637-024-01494-4

By:

Zhao, Shaoli;
Sun, Wei;
Sun, Jichun;
Peng, Liping;
Wang, Chunjiang

Publication type:

Article

The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 108, doi. 10.1007/s10637-024-01492-6

By:

Li, Meihui;
Wang, Xinyuan;
Gong, Jiali;
Lu, Hongyang

Publication type:

Article

Dual PTCH2 mutation [Ser391*, Leu104Pro]: unveiling a potential new genetic susceptibility factor for glioma development.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 126, doi. 10.1007/s10637-024-01491-7

By:

Li, Xiang;
Wu, Yingting;
Han, Tiantian;
Ding, Ran;
Kong, Rongrong;
Chen, Siqi;
Luo, Ningning;
Jin, Mingji;
Chen, Dongsheng;
Zhang, Ping

Publication type:

Article

Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 157, doi. 10.1007/s10637-024-01490-8

By:

Ma, Saisai;
Xu, Yichen;
Liu, Minmin;
Wu, Shuaida;
Zhang, Ye;
Xia, Hongyan;
Lu, Ji;
Zhan, Yang

Publication type:

Article

A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 60, doi. 10.1007/s10637-024-01489-1

By:

Boland, Patrick M.;
Lenz, Heinz-Josef;
Ciombor, Kristen K.;
Florou, Vaia;
Pishvaian, Michael J.;
Cusnir, Michael;
Cohen, Deirdre;
Guo, Jessie Y.;
Tang, Min;
Rajagopalan, Prabhu;
Wiley, Sandra E.;
Ghalie, Richard G.;
Hochster, Howard S.

Publication type:

Article

5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 30, doi. 10.1007/s10637-024-01488-2

By:

Zhao, Siyuan;
Wang, Tiansi;
Shi, Kourong;
Li, Ting;
Zhu, Qiuzhen;
Li, Yuan;
Xin, Beiwei;
Wu, Xin;
Fan, Wei

Publication type:

Article

Vebreltinib: a promising milestone in targeted therapy for METex14-mutant NSCLC.

Published in:

2025

By:

Ma, LinRui;
Meng, WeiKang;
Jiang, WenJuan

Publication type:

Letter

Comprehensive study of gene fusions in sarcomas.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 3, doi. 10.1007/s10637-024-01486-4

By:

Chen, Nan;
Zhang, Qin;
Sun, Lei;
You, Xia;
Chen, Siqi;
Chen, Dongsheng;
Yang, Fengkun

Publication type:

Article

Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 81, doi. 10.1007/s10637-024-01485-5

By:

Liu, Rui;
Ji, Zhi;
Wang, Xia;
Xin, Jiaqi;
Zhu, Lila;
Ge, Shaohua;
Zhang, Le;
Bai, Ming;
Ning, Tao;
Yang, Yuchong;
Li, Hongli;
Deng, Ting;
Ba, Yi

Publication type:

Article

Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study.

Published in:

Investigational New Drugs, 2025, v. 43, n. 1, p. 18, doi. 10.1007/s10637-024-01468-6

By:

Jiang, Yi;
Su, Ke;
Li, Han;
Wang, Chenjie;
Wu, Zhenying;
Chen, Jiali;
Zhang, Zhiyao;
He, Kun;
Han, Yunwei

Publication type:

Article